N,N-dimethyl-4-(5-thiophen-2-yl-1,3,4-oxadiazol-2-yl)aniline

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N-dimethyl-4-(5-thiophen-2-yl-1,3,4-oxadiazol-2-yl)aniline
• 化学式: C₁₄H₁₃N₃OS
• 分子量: 271.34
• InChiKey: ZWZJQNSDEXBTRV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  70.4
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• PROBE FOR DIAGNOSIS OF CONFORMATIONAL DISEASE
  申请人：TOHOKU UNIVERSITY

  公开号：EP1967517A1

  公开（公告）日：2008-09-10

  The invention provides a probe compound useful for early diagnosis of conformation disease, a composition and a kit comprising it for diagnosis for conformation disease, and a medical composition for treatment and/or prevention of conformation disease.

  本发明提供了一种用于早期诊断构象疾病的探针化合物、一种用于诊断构象疾病的组合物和包含该化合物的试剂盒，以及一种用于治疗和/或预防构象疾病的医用组合物。
• BENZOXAZOLE DERIVATIVES
  申请人：Tohoku University

  公开号：EP2103611A1

  公开（公告）日：2009-09-23

  It is intended to provide a benzoxazole derivative or a pharmaceutically acceptable salt or solvate thereof which is useful in the early diagnosis of a conformation disease; a composition or a kit containing the same for diagnosing a conformation disease; a medical composition for ttreating and/or preventing a conformation disease; and so on.

  本发明旨在提供一种苯并恶唑衍生物或其药学上可接受的盐或溶液，该衍生物或其药学上可接受的盐或溶液可用于构象疾病的早期诊断；一种含有该衍生物或其药学上可接受的盐或溶液的组合物或试剂盒，该组合物或试剂盒可用于构象疾病的诊断；一种用于治疗和/或预防构象疾病的医用组合物，等等。
• DIAGNOSTIC PROBE FOR CONFORMATION DISEASE
  申请人：Kudo Yukitsuka

  公开号：US20090185975A1

  公开（公告）日：2009-07-23

  The invention provides a probe compound useful for early diagnosis of conformation disease, a composition and a kit comprising it for diagnosis for conformation disease, and a medical composition for treatment and/or prevention of conformation disease.
• ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE
  申请人：Magenta Therapeutics Inc.

  公开号：US20210220408A1

  公开（公告）日：2021-07-22

  The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies, such as cancer, by administration of these aryl hydrocarbon receptor antagonists. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells. The disclosure further relates to pharmaceutical compositions comprising the compounds and methods of treating or preventing a disease in which aryl hydrocarbon receptor plays a role.
• US7910579B2
  申请人：——

  公开号：US7910579B2

  公开（公告）日：2011-03-22